Hello, we're Nonacus
Your NGS partner in detection, monitoring, and guiding treatment with a validated end-to-end workflow
From Brainstorm to Breakthrough
The Nonacus origin story
Our story begins with two scientists and a genomics problem they wanted to solve.
When Chris Sale and Lee Silcock founded Nonacus in 2015 they had one singular purpose - to develop non-invasive DNA tests that would change the way genomic diagnostics was done.
Based on the Latin term 'non acus' meaning 'no needle', Nonacus symbolises the company's mission- to move away from intrusive, risky diagnostic procedures like tissue biopsies or amniocentesis towards less invasive testing to improve patient experiences, redefine standard of care and open up new possibilities for monitoring and treatment.
GALEAS Bladder, our first truly non-invasive test, is able to detect bladder cancer from a urine sample – not a needle in sight.
Our mission
We’re creating a world where early cancer diagnosis, detection and management is simple and universally available.
A decade of innovation
As Nonacus approaches its 10th anniversary in 2025, it's a testament to what can be achieved by the unwavering ambition of a dedicated team. We've witnessed a remarkable decade of growth and innovation, fuelled by the vision of our co-founders.
Looking ahead, we're excited to embark on the next chapter. This includes expanding our global reach, building a vibrant community of scientists and researchers, and continuously pushing the boundaries of NGS technology.
Meet Jeff, our CEO
"Nonacus is solving problems that’ll improve the lives of billions worldwide through the universal availability of early cancer diagnosis, detection and management. I'm honored to lead this amazing team that has already achieved so much. Together, we will continue to innovate and deliver groundbreaking solutions that transform patient care and advance the future of precision medicine, focusing on improving patient outcomes and making a meaningful difference to people's lives.”
Jeff Bousfield
CEO, Nonacus
Meet the family
Advanced Genomics Group Ltd
Nonacus is proud to be part of the Advanced Genomics group, a global group of companies striving to improve patient experiences, redefine standard of care and open up new possibilities for monitoring and treatment.
2015
Nonacus was founded by Chris Sale and Lee Silcock in 2015 to develop non-invasive DNA tests that moved away from intrusive, risky diagnostic procedures towards less invasive testing.
Today, Nonacus is a leading provider of innovative testing technologies to the genomic healthcare sector through the use of cell-free circulating DNA as a non-invasive diagnostic tool and deployment of their advanced liquid biopsy platform. Nonacus is committed to enabling decentralised, cost-effective and cutting-edge cancer genomics, democratising early cancer detection and monitoring on a global basis.
2022
Chris and Lee launched Informed Genomics in January 2022 to provide a high standard of clinical laboratory testing. By offering Nonacus’ innovative products as part of an end-to-end, high quality clinical or research service, Informed Genomics helps more patients to benefit from these innovative solutions.
Today, with services accredited to UKAS ISO 15189 – equal to standards maintained by NHS laboratories – and retaining quality at the heart of its operations, Informed Genomics delivers services to the NHS, private healthcare providers and researchers across the world. Its portfolio of excellent services continues to grow, based on Nonacus products but also innovations from outside the group, in order to continue transforming healthcare through innovative genomic testing.
2023
In October 2023, Advanced Genomics announced the opening of its Taiwan headquarters. Advanced Genomics APAC enables the Group to expand into markets such as Japan, South Korea, New Zealand, Australia, mainland China, and Southeast Asia
Its core mission is to provide hospitals, clinics, laboratories, enterprises, and patients across the continent with state-of-the-art testing technology, high-quality equipment, and technical support to top research institutions.
